Cargando…
Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
BACKGROUND: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide. OBJECTIVES: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges...
Autores principales: | Robertson, Andrew Kyle Henderson, Ramogida, Caterina Fortunata, Schaffer, Paul, Radchenko, Valery |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249690/ https://www.ncbi.nlm.nih.gov/pubmed/29658444 http://dx.doi.org/10.2174/1874471011666180416161908 |
Ejemplares similares
-
Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced (225)Ac
por: Ramogida, Caterina F., et al.
Publicado: (2019) -
A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
por: Kelly, James M., et al.
Publicado: (2021) -
Impact of radiopharmaceutical therapy ((177)Lu, (225)Ac) microdistribution in a cancer-associated fibroblasts model
por: Tranel, Jonathan, et al.
Publicado: (2022) -
Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023) -
Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis
por: Sgouros, George, et al.
Publicado: (2021)